Zafgen says another patient dies in obesity drug trial; Negative news about statins affects their use, study finds;

> Zafgen ($ZFGN), the drugmaker that suspended an obesity drug trial in October after a patient died, said another trial participant has perished, this time from a blocked artery in the lung. Report

> Negative news about the risks or side effects of statin drugs prompts people to ratchet back their use of the drug, increasing risks of heart attacks and strokes, a new study found. Report

> BioMarin Pharmaceutical ($BMRN) is still optimistic about approval prospects for its Duchenne muscular dystrophy drug, which came in for intense criticism at an FDA advisory panel meeting last week. Report

> Horizon Pharma ($HZNP) nabbed European approval for Ravicti, its new add-on drug for urea cycle disorders. Report

And Finally... Forget Adderall for a workplace boost; some Silicon Valley workers reportedly are taking small doses of the psychedelic drug LSD to make themselves more productive. Report

Suggested Articles

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.